Senores Pharmaceuticals raises ₹23.75 crore with preferential warrants
Verified article - details checked for accuracy.
Senores Pharmaceuticals secured a ₹23.75 crore cash boost through a preferential warrant issue, with the potential to raise ₹95.04 crore if all warrants are exercised.
- The board approved the issue of 1,170,000 convertible warrants on 28 Mar 2026 at an exercise price of ₹812 per warrant (₹203 payable at allotment, ₹609 on conversion).
- Immediate proceeds total ₹23.75 crore, and full conversion would bring an extra ₹71.25 crore, lifting total possible proceeds to ₹95.04 crore over the next 18 months.
- Regulatory clearances from BSE and NSE were obtained on 13 Mar 2026, and SEBI lock‑in rules apply to the new shares.
- Assuming 100 % conversion, promoter holdings rise modestly from 23.30% to 25.26%, indicating limited dilution.
- The funds can be used for R&D, working capital, or strategic moves, while the actual capital raised depends on how many warrants are ultimately exercised.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.